167 related articles for article (PubMed ID: 17968938)
1. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril.
Gliddon AE; Doré CJ; Black CM; McHugh N; Moots R; Denton CP; Herrick A; Barnes T; Camilleri J; Chakravarty K; Emery P; Griffiths B; Hopkinson ND; Hickling P; Lanyon P; Laversuch C; Lawson T; Mallya R; Nisar M; Rhys-Dillon C; Sheeran T; Maddison PJ
Arthritis Rheum; 2007 Nov; 56(11):3837-46. PubMed ID: 17968938
[TBL] [Abstract][Full Text] [Related]
2. Lack of efficacy of quinapril on vascular damage in limited cutaneous systemic sclerosis.
Guiducci S; Cerinic MM
Nat Clin Pract Rheumatol; 2008 Jun; 4(6):288-9. PubMed ID: 18461063
[TBL] [Abstract][Full Text] [Related]
3. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
[TBL] [Abstract][Full Text] [Related]
4. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis.
Herrick AL; van den Hoogen F; Gabrielli A; Tamimi N; Reid C; O'Connell D; Vázquez-Abad MD; Denton CP
Arthritis Rheum; 2011 Mar; 63(3):775-82. PubMed ID: 21360507
[TBL] [Abstract][Full Text] [Related]
5. The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Bello RJ; Cooney CM; Melamed E; Follmar K; Yenokyan G; Leatherman G; Shah AA; Wigley FM; Hummers LK; Lifchez SD
Arthritis Rheumatol; 2017 Aug; 69(8):1661-1669. PubMed ID: 28426903
[TBL] [Abstract][Full Text] [Related]
6. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
7. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery.
Rouleau JL; Warnica WJ; Baillot R; Block PJ; Chocron S; Johnstone D; Myers MG; Calciu CD; Dalle-Ave S; Martineau P; Mormont C; van Gilst WH;
Circulation; 2008 Jan; 117(1):24-31. PubMed ID: 18071079
[TBL] [Abstract][Full Text] [Related]
8. [Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial].
Correa MJ; Mariz HA; Andrade LE; Kayser C
Rev Bras Reumatol; 2014; 54(6):452-8. PubMed ID: 25458027
[TBL] [Abstract][Full Text] [Related]
9. The effect of angiotensin converting enzyme inhibition on myocardial function and blood pressure after coronary artery bypass surgery--a randomised study.
Webb CM; Underwood R; Anagnostopoulos C; Bennett JG; Pepper J; Lincoln C; Collins P
Eur J Cardiothorac Surg; 1998 Jan; 13(1):42-8. PubMed ID: 9504729
[TBL] [Abstract][Full Text] [Related]
10. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators.
Pflugfelder PW; Baird MG; Tonkon MJ; DiBianco R; Pitt B
J Am Coll Cardiol; 1993 Nov; 22(6):1557-63. PubMed ID: 8227822
[TBL] [Abstract][Full Text] [Related]
11. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
[TBL] [Abstract][Full Text] [Related]
12. Assessing the clinical need for short-term conversion from oral to parenteral angiotensin converting enzyme inhibitor therapy in hypertensive patients. A quinapril to quinaprilat placebo-controlled model.
Whelton A; McCormick L; Wombolt D; Goldstein R; Canter D
Eur Heart J; 1997 Jan; 18(1):140-7. PubMed ID: 9049526
[TBL] [Abstract][Full Text] [Related]
13. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
[TBL] [Abstract][Full Text] [Related]
14. Influence of clinical features on the health status of patients with limited cutaneous systemic sclerosis.
Gliddon AE; Doré CJ; Maddison PJ;
Arthritis Rheum; 2006 Jun; 55(3):473-9. PubMed ID: 16739187
[TBL] [Abstract][Full Text] [Related]
15. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
Black CM; Halkier-Sørensen L; Belch JJ; Ullman S; Madhok R; Smit AJ; Banga JD; Watson HR
Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
[TBL] [Abstract][Full Text] [Related]
16. A multicentre, double-blind, placebo-controlled trial of quinapril in mild, chronic heart failure.
Northridge DB; Rose E; Raftery ED; Lahiri A; Elder AT; Shaw TR; Henderson E; Dargie HJ
Eur Heart J; 1993 Mar; 14(3):403-9. PubMed ID: 8458362
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.
Denton CP; Hachulla É; Riemekasten G; Schwarting A; Frenoux JM; Frey A; Le Brun FO; Herrick AL;
Arthritis Rheumatol; 2017 Dec; 69(12):2370-2379. PubMed ID: 29193819
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Botulinum Toxin in Adults with Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
Senet P; Maillard H; Diot E; Lazareth I; Blaise S; Arnault JP; Pistorius MA; Boulon C; Cogrel O; Warzocha U; Rivière S; Malloizel-Delaunay J; Servettaz A; Sassolas B; Viguier M; Monfort JB; Janique S; Vicaut E;
Arthritis Rheumatol; 2023 Mar; 75(3):459-467. PubMed ID: 36066501
[TBL] [Abstract][Full Text] [Related]
19. Prevention of vascular damage in scleroderma with angiotensin-converting enzyme (ACE) inhibition.
Maddison P
Rheumatology (Oxford); 2002 Sep; 41(9):965-71. PubMed ID: 12209028
[TBL] [Abstract][Full Text] [Related]
20. Controlled multicenter study with quinapril, hydrochlorothiazide, and combination in patients with moderate to severe hypertension.
Romero R; Castellote E; Ocón J; Wagner B
J Cardiovasc Pharmacol; 1995 Jul; 26(1):114-8. PubMed ID: 7564350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
